TL;DR
This large-scale cohort study of over 31,000 births in Beijing demonstrates that while periconceptional folic acid only (FAO) supplementation is standard for preventing neural tube defects, multiple micronutrients with folic acid (MMFA) may be more effective at improving birth outcomes. High compliance with MMFA was specifically linked to increased average birth weight and a significantly reduced risk of newborns being Small for Gestational Age (SGA).
What Problem Does This Paper Address?
Maternal folic acid supplementation is globally recognized as the gold standard for preventing neural tube defects (NTDs). However, its impact on newborn birth weight—a critical indicator of long-term health—remains a subject of intense debate. Previous studies have yielded conflicting results: some suggest folic acid promotes fetal growth, while others find no effect or even a potential risk of lower birth weight with high doses.
Furthermore, there is a lack of clarity regarding the "formula" of supplementation. Most research doesn't distinguish between taking Folic Acid Only (FAO) versus Multiple Micronutrients containing Folic Acid (MMFA). The authors sought to determine how the type of supplement, the timing of initiation (pre- vs. post-conception), and the level of compliance influence birth weight and the risks of being Small for Gestational Age (SGA) or Large for Gestational Age (LGA).
Methods
The researchers conducted a retrospective cohort study using data from a population-based prenatal health care system in Beijing. They employed:
- Generalized Linear Models: To evaluate the association between supplementation and continuous birth weight.
- Logistic Regression Models: To calculate adjusted odds ratios (aOR) for the risk of SGA and LGA.
- Compliance Metrics: "High compliance" was strictly defined as taking supplements for 8 or more days out of every 10.
- Adjustments: The models controlled for a wide array of confounding factors, including maternal age, BMI, education, parity, delivery year, and gestational complications like diabetes and anemia.
Datasets
The study utilized data from the Prenatal Health Care System (PHCS) at the Tongzhou Maternal and Child Health Hospital in Beijing.
- Scope: 31,107 singleton births recorded between 2015 and 2018.
- Data Quality: Because the PHCS is a networked system, data is collected in real-time during the first trimester, significantly reducing the "recall bias" often found in studies where mothers are interviewed after delivery.
Key Insights and Ideas
- The Synergy of Micronutrients: The most striking insight is that MMFA outperformed FAO. While FAO primarily prevents NTDs, the addition of other vitamins and minerals (like iron, calcium, and selenium) appears to have a synergistic effect on fetal growth, leading to higher average birth weights.
- Compliance is King: The benefits of supplementation were largely dependent on high compliance. Low-compliance users saw negligible improvements in birth weight, highlighting that the "dose-response" relationship is critical in prenatal nutrition.
- Corrective, Not Just Additive: Supplementation reduced the risk of SGA (the "lower end" of birth weights) but did not increase the risk of LGA (the "upper end"). This suggests that folic acid and micronutrients act as a protective buffer for fetal development rather than a general growth stimulant that could lead to macrosomia (excessive birth weight).
- Timing Flexibility: Interestingly, the protective effect against SGA was observed regardless of whether the mother started the supplements before or after conception, provided they were taken during the critical periconceptional window.
Key Results
- Birth Weight Increase: Newborns of mothers with high compliance to MMFA had a median birth weight 25.59g higher (95% CI: 6.49–44.69) than those who took no supplements. FAO had no significant impact on median birth weight.
- SGA Risk Reduction: Any periconceptional folic acid supplementation reduced SGA risk (aOR = 0.81). When broken down by formula with high compliance:
- FAO: 17% reduction in SGA risk (aOR = 0.83).
- MMFA: 26% reduction in SGA risk (aOR = 0.74).
- LGA Impact: No significant association was found between any form of folic acid supplementation and the risk of LGA.
Limitations and Future Work
The authors acknowledge several limitations that provide a roadmap for future research:
- Dosage Specifics: The study did not collect exact milligram dosages for the supplements, which vary between FAO (typically 0.4mg in China) and various MMFA brands (often 0.8mg).
- Lifestyle Confounders: Data on physical activity and specific dietary patterns (beyond Han ethnicity commonalities) were not available.
- Genetic Factors: The study did not account for MTHFR gene polymorphisms, which significantly affect how individuals metabolize folate.
- Temporal Scope: The data focused only on the periconceptional period and the first trimester; the impact of continued supplementation through the second and third trimesters remains unexamined in this specific cohort.
Future work could integrate genetic screening and more granular dosage tracking to create personalized prenatal supplementation guidelines.
Summary updated